| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5833432 | International Immunopharmacology | 2013 | 7 Pages |
Abstract
CAPE has a significant anti-diabetic effect on mice in vivo. This anti-diabetic effect may be related to its anti-inflammatory and angiostatic effects. It also reduced angiogenic factors which may shift the equilibrium to the angiostatic effect of CAPE. These findings provide the validity of CAPE as anti-diabetic agent in the special model of CsA/STZ and could be relevant in the future for human diabetes.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Soha H. Abduljawad, Mohamed F. El-Refaei, Nermeen N. El-Nashar,